R&D News | pharmaphorum

News

Cannabinoids show promise in acute migraine clinical trial

Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine, according to a new clinical trial.

News

RNA therapy firm Avidity files $400m placement

Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine

News

Pfizer’s new cancer unit sees eight new blockbusters by 2030

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest

News

Ironwood felled by mixed data in short bowel syndrome trial

Ironwood Pharma has issued an upbeat assessment of phase 3 trial data with apraglutide for short bowel syndrome (SBS), but missed secondary outcome measures led to a sharp

News

Palatin pummelled as dry eye therapy underwhelms in phase 3

Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.

News

Ginkgo Bioworks scales up again with M&A frenzy

Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to

Cannabinoids show promise in acute migraine clinical trial

RNA therapy firm Avidity files $400m placement

Pfizer’s new cancer unit sees eight new blockbusters by 2030

Ironwood felled by mixed data in short bowel syndrome trial

Palatin pummelled as dry eye therapy underwhelms in phase 3

Ginkgo Bioworks scales up again with M&A frenzy

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks